sundry articles: ovarian cancer Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present


Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Sunday, June 19, 2016

sundry articles: ovarian cancer

… carboplatin or pegylated liposomal doxorubicin in adults with folate receptor alpha (FR {alpha})-positive advanced epithelial ovarian cancer (EOC), primary peritoneal …

DM O'Malley, LP Martin, KN Moore, DL Nepert… - ASCO Annual Meeting …, 2016
Background: Elevated FRα expression is characteristic of a number of solid tumors,
including EOC and endometrial cancer, thereby providing an attractive candidate for
targeted therapeutic strategies in these indications. Mirvetuximab soravtansine (IMGN853) ...

Ovarian cancer pathway map development as an approach to identifying priority areas for quality improvement in Ontario.

H Mackay, J Soobrian, SE Ferguson, W Faught, J Ross… - ASCO Annual Meeting …, 2016
Background: Disease Pathway Management (DPM) is the unifying approach to the way in
which Cancer Care Ontario (CCO) sets priorities for cancer control, plans cancer services
and improves the quality of care in Ontario. In January 2015, DPM began developing an ...

The TGFβ pathway stimulates ovarian cancer cell proliferation by increasing IGF1R levels

E Alsina‐Sanchís, A Figueras, Á Lahiguera, A Vidal… - International Journal of …, 2016
ABSTRACT In a search for new therapeutic targets for treating epithelial ovarian cancer we
analyzed the Transforming Growth Factor Beta (TGFβ) signaling pathway in these tumors.
Using a TMA with patient samples we found high Smad2 phosphorylation in ovarian ...

Topotecan (T){+/-} sorafenib (S) in platinum-resistant ovarian cancer (PROC): A double-blind placebo-controlled randomized NOGGO-AGO intergroup Trial--TRIAS.

J Sehouli, F Hilpert, S Mahner, T Neunhoeffer, P Harter… - ASCO Annual Meeting …, 2016
Background: Sorafenib (S), a multi TK-inhibitor in combination with topotecan (T), a
topoisomerase inhibitor showed preclinical synergistic effects in ovarian cancer but critical
toxicity. To avoid cumulative toxicity effects we selected the 5-day schedule of T and a ...

Glucocorticoid receptor expression and survival in ovarian cancer.

JT Veneris, KM Darcy, P Mhawech-Fauceglia… - ASCO Annual Meeting …, 2016
Background: Despite debulking surgery and platinum-based treatment, most ovarian
cancers recur and develop chemotherapy resistance. In cell lines and xenografts,
glucocorticoid receptor (GR) regulation of anti-apoptotic gene expression is associated ...

Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target

U Saini, S Naidu, AC ElNaggar, HK Bid, JJ Wallbillich… - Oncogene, 2016
Abstract Although activation of the STAT3 pathway has been associated with tumor
progression in a wide variety of cancer types (including ovarian cancer), the precise
mechanism of invasion and metastasis due to STAT3 are not fully delineated in ovarian ...

Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium

RA Cannioto, MJ LaMonte, LE Kelemen, HA Risch… - British Journal of Cancer, 2016
Background: Little is known about modifiable behaviours that may be associated with
epithelial ovarian cancer (EOC) survival. We conducted a pooled analysis of 12 studies from
the Ovarian Cancer Association Consortium to investigate the association between pre- ...

[HTML] A Novel Tumor-Specific Agent for Intraoperative Near-Infrared Fluorescence Imaging: A Translational Study in Healthy Volunteers and Patients with Ovarian Cancer

CES Hoogstins, QRJG Tummers, KN Gaarenstroom… - Clinical Cancer Research, 2016
Purpose: Completeness of cytoreductive surgery is a key prognostic factor for survival in
patients with ovarian cancer. The ability to differentiate clearly between malignant and
healthy tissue is essential for achieving complete cytoreduction. Using current approaches ...

Prevalence of somatic mutations in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1 study).

E Hahnen, KH Baumann, A Heimbach, A Reuss… - ASCO Annual Meeting …, 2016
Background: The mutation status of BRCA1/2 and other ovarian cancer (OC) predisposition
genes is a valuable prognostic and predictive factor and widely used for clinical decision
making. However, data on the prevalence of clearly somatic BRCA1/2alterations is sparse ...

Ovarian cancer laparoscopic hysterectomy and staging in a patient with history of intraperitoneal renal transplant.

M Andrikopoulou, P Vetere, FR Nezhat - Gynecologic oncology, 2016
OBJECTIVE: Ovarian cancer laparoscopic staging of patient with intraperitoneal renal
transplant. METHODS: 43-year-old female with intra-peritoneal renal transplant was referred
status post laparoscopic bilateral ovarian cystectomies. The pathology report revealed ...

Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.

M Hijaz, J Chhina, I Mert, M Taylor, S Dar, Z Al-Wahab… - Gynecologic oncology, 2016
OBJECTIVES: BRCA mutated ovarian cancers show increased responsiveness to PARP
inhibitors. PARP inhibitors target DNA repair and provide a second hit to BRCA mutated
tumors, resulting in" synthetic lethality". We investigated a combination of metformin and ...


M Bagnoli, A Granata, R Nicoletti, B Krishnamachary… - Frontiers in Oncology, 2016
Compared to normal differentiated cells, cancer cells require a metabolic reprogramming to
support their high proliferation rates and survival. Aberrant choline metabolism is a fairly
new metabolic hallmark reflecting the complex reciprocal interactions between oncogenic ...

Usefulness of Canadian Public Health Insurance Administrative Databases to Assess Breast and Ovarian Cancer Screening Imaging Technologies for BRCA1/2 …

G Larouche, J Chiquette, M Plante, S Pelletier… - Canadian Association of …, 2016
Purpose In Canada, recommendations for clinical management of hereditary breast and
ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation have
been available since 2007. Eight years later, very little is known about the uptake of ...

… -003) in combination with carboplatin plus either paclitaxel or pegylated liposomal doxorubicin (PLD) in subjects with low CA125 platinum-sensitive ovarian cancer.

TJ Herzog, SA Ghamande, H Gabra, DK Armstrong… - ASCO Annual Meeting …, 2016
Background: Farletuzumab (FAR) is a humanized monoclonal antibody that binds to folate
receptor-alpha which is highly expressed in epithelial ovarian cancer (EOC) and largely
absent from normal tissue. FAR potentially has anti-tumor activity via antibody dependent ...

Bevacizumab after bevacizumab in platinum-sensitive recurrent ovarian cancer: A subgroup analysis of GOG0213.

RL Coleman, MF Brady, TJ Herzog, DK Armstrong… - ASCO Annual Meeting …, 2016
Background: In GOG 213, a phase III randomized trial designed to determine the impact of
secondary cytoreduction and/or incorporation of anti-angiogenesis therapy on overall
survival (OS) in recurrent platinum-sensitive EOC, we recently reported that the integration ...

The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols

R Mercieca-Bebber, M Friedlander, PS Kok, M Calvert… - Quality of Life Research, 2016
Purpose Patient-reported outcomes (PROs) provide the patient's perspective of the impact of
treatment. Evidence suggests that PRO content of randomised controlled trials (RCTs)
protocols is generally sub-optimal. This study aimed to describe and evaluate the PRO- ...

Exome sequencing of ovarian cancer patients to identify variants predictive of sensitivity to chemotherapy.

A Semaan, K Delfino, A Wilber, K Robinson, L Brard… - ASCO Annual Meeting …, 2016
Background: Studies have found that genetic determinates can predict response to
chemotherapy in some cancer patients. However little is known about ovarian cancer. By
using exome sequencing, potential alleles predictive of sensitivity to cisplatin treatment ...

Association of MiR-26b mediated doxorubicin resistance signature with poor prognosis in epithelial ovarian cancer (EOC).

I Korsunsky, J Parameswaran, I Shapira, M Oswald… - ASCO Annual Meeting …, 2016
Background: MicroRNAs (miRNA) have been established as key regulators of tumor gene
expression as well as prime biomarker candidates for clinical phenotypes. We analyzed the
regulatory structure of miRNAs and their colocalized gene targets in EOC tissue to ...

Correlation of mutation status between tissue and blood-drop liquid biopsies from ovarian cancer patients following chemotherapy.

AI Londono, CH Yeh, RD Alvarez, CA Leath… - ASCO Annual Meeting …, 2016
Background: Peripheral circulating cell-free DNA (cfDNA) has great promise for targeted
therapy and monitoring tumor clonal evolution during treatment, thus overcoming the
limitations of invasive tissue biopsy. However, the requirement of large sample input, low ...

Phase II trial of enzalutamide in patients with androgen receptor positive (AR+) ovarian, primary peritoneal or fallopian tube cancer and one, two or three prior …

RN Grisham, DD Giri, A Iasonos, Q Zhou, J Girshman… - ASCO Annual Meeting …, 2016
... Abstract Disclosures. Abstract TPS5602. Background: Approximately 75% of women with
epithelial ovarian cancer (OC) present with advanced disease. The majority of these women
will ultimately recur and require life-long treatment for their disease. ...


Post a Comment

Your comments?